Pharmacokinetic properties of a drug, and selection and correct usage of an appropriate delivery device, are factors that can affect the outcome of inhaled therapyThe use of nebulization can overcome problems that are associated with other delivery systems used for inhalation therapyThe
Results with respect to systemic exposure to beclometasone-I7-monopropionate (BI7MP) (the active metabolite of BDP) and systemic effects on the hypothalamic-pituitary-adrenal (HPA) axis were determined by evaluation of a number of pharmacokinetic parameters for plasma B I7MP and serum and urinary cortisol, respectively A statistically significantly greater peak plasma concentration (C,d of B I7MP was reported with BDP via MDI ( I587 pg ml-l) compared with BDP I 600 pg (455 pg ml-l) and BDP 3200 pg suspensions for nebulization (758 pg ml-l), and was achieved more rapidly (T,d (I .3 h, 3 h, and 2.5 h, respectively). In addition, elimination half-life (t&) was statistically significantly shorter with BDP via MDI (4.6 h) than with both dosages of BDP suspensions for nebulization (7.4 h and 6.3 h with I600 pg and 3200 pg, respectively), as was mean residence time (MRT) (5.4 h, I I . I h, and IO.0 h, respectively).Total systemic exposure to B I7MP (as determined by the area under the concentration-time curve: AUC,) was comparable for BDP via MDI (6883 pg ml-1 h-1) and BDP 3200 pg suspension for nebulization (820 I pg ml-1 h-l), but significantly greater than with BDP I 600 pg suspension for nebulization (4870 pg ml -1 ; WO.05 vs BDP via MDI). All treatments were well tolerated, and no significant differences were found between them with respect to the serum or urinary cortisol pharmacokinetic parameters assessed. In conclusion, the results of this study demonstrate that BDP suspension for nebulization 3200 pg given via a nebulizer and BDP I600 pg given via an MDI are equivalent in terms of systemic exposure to B I7MP and systemic effects on the HPA axis, with BDP suspension for nebulization having a potentially more prolonged activity It confirms that use of a double dose of BDP suspension for nebulization administered by nebulizer compared with BDP given via metered-dose inhalation is justified and poses no risk with regard to safety. A total of I8 plasma samples were taken over 24 h after drug administration for determination of plasma BDP and B I7MP levels by means of validated chromatographic methods (LC-MS/MS), with a quantitation limit of 20 pg ml-', at the Phoenix International Life Sciences Laboratories (Canada). A total of IO serum samples were taken over 24 h during the run-in period and after drug administration to measure serum cortisol levels, and urine was collected over 24 h during the same periods to measure cortisol urinary excretion. Cortisol in both serum and urine was determined by means of a validated radioimmunoassay (RIA) method, with a quantitation limit of IO ng ml-', at SGS-Biopharma Laboratories (Belgium During the run-in period, serum cortisol concentrations dropped from I22 ng ml-r at 8.00 a.m. to 17 ng ml-r at midnight before increasing again until 8.00 am the following morning.With all BDP treatments, levels fell more rapidly after administration than during the run-in, such that after 6 h they were below 25 ng ml-r (compared with just over 75 ng ml-' during the run-in) (Figure 2) . From 6 h to I6 h after administration, serum cortisol levels remained fairly stable at a minimum value and then increased in a similar manner for all treatments to the run-in period until 8.00 a.m. the following day. No significant differences were found between the treatments with respect to any of the pharmacokinetic parameters evaluated for serum cortisol (Table 3 ). Cortisol urinary excretion over 24 hours was in the normal range (20-90 pg 24 h-r according to the RADIM RIA lkit) in all subjects except for one, who had values of 18.8 pg 24 h-l with BDP via MDI and 13.8 pg 24 h-l with BDP 3200 yg suspension for nebulization. Cortisol urinary excretion normalized for creatinine was virtually unchanged compared with run-in with BDP 1600 I-18 suspension nebulization, and approximately IO% and 20% lower with BDP 3200 pg suspension for nebulization and BDP via MDI, respectively (Table 4 and Figure 3 ( Table 4) . Again, differences between treatments were not statistically significant.
INTRODUCTION

DISCUSSION
This study was designed to evaluate the systemic exposure to B I7MP and safety associated with single-dose administrations of two different dosages of a new formulation of BDP suspension given via a nebulizer and BDP given via an MDI in healthy volunteers.
Two previous studies have compared the systemic bioavailability of budesonide delivered via nebulizer and MDI with conflicting results. One study showed considerable suppression of morning plasma cortisol levels with high-dose (4 mg) budesonide given via MDI, but no effect was seen with the same dose of budesonide given via nebulizer (8). Conversely, a second study in adult asthmatics showed a clear dose-related effect of 0.8 mg budesonide delivered via MDI and I mg and 4 mg nebulized budesonide on plasma budesonide and plasma cortisol levels, that was independent of the device (9). It has been suggested that different types of nebulizers may influence the amount of drug that is delivered to the lungs, and subsequently the drug's bioavailability (I 0), and this may explain the inconsistencies to date. The results from this study, using the Pari Turbo Boy@ nebulizer, demonstrate significant differences between BDP administered via MDI and BDP suspension for nebulization with respect to several of the pharmacokinetic parameters assessed for plasma B I7MP. Administration of BDP via MDI was associated with a more rapid rise to peak plasma concentrations of B I7MP (thus suggesting rapid absorption of BDP and subsequent metabolism to B I7MP), greater peak plasma concentrations of BI 7MP and a notably shorter elimination half-life of plasma B I7MP than both the same dose and double the dose of BDP suspension for nebulization. 
